Adamis Pharmaceuticals Corporation (ADMP) & Tetraphase Pharmaceuticals (TTPH) Head to Head Review
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) and Tetraphase Pharmaceuticals (NASDAQ:TTPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.
Institutional & Insider Ownership
10.1% of Adamis Pharmaceuticals Corporation shares are owned by institutional investors. Comparatively, 41.7% of Tetraphase Pharmaceuticals shares are owned by institutional investors. 9.6% of Adamis Pharmaceuticals Corporation shares are owned by insiders. Comparatively, 5.5% of Tetraphase Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Adamis Pharmaceuticals Corporation and Tetraphase Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Adamis Pharmaceuticals Corporation||-158.51%||-69.03%||-47.51%|
Earnings and Valuation
This table compares Adamis Pharmaceuticals Corporation and Tetraphase Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Adamis Pharmaceuticals Corporation||$11.39 million||14.73||-$18.97 million||N/A||N/A|
|Tetraphase Pharmaceuticals||$5.01 million||65.93||-$104.99 million||($2.81)||-2.30|
Adamis Pharmaceuticals Corporation has higher revenue and earnings than Tetraphase Pharmaceuticals.
Volatility & Risk
Adamis Pharmaceuticals Corporation has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, Tetraphase Pharmaceuticals has a beta of 2.57, suggesting that its share price is 157% more volatile than the S&P 500.
This is a summary of current recommendations for Adamis Pharmaceuticals Corporation and Tetraphase Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Adamis Pharmaceuticals Corporation||0||0||3||0||3.00|
Adamis Pharmaceuticals Corporation currently has a consensus target price of $9.83, suggesting a potential upside of 83.80%. Tetraphase Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 116.38%. Given Tetraphase Pharmaceuticals’ higher possible upside, analysts clearly believe Tetraphase Pharmaceuticals is more favorable than Adamis Pharmaceuticals Corporation.
Adamis Pharmaceuticals Corporation beats Tetraphase Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
About Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
Receive News & Stock Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related stocks with our FREE daily email newsletter.